80 related articles for article (PubMed ID: 35153452)
21. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
22. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
23. Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation.
Alamri MA; Tahir Ul Qamar M; Afzal O; Alabbas AB; Riadi Y; Alqahtani SM
J Mol Liq; 2021 May; 330():115699. PubMed ID: 33867606
[TBL] [Abstract][Full Text] [Related]
24. Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic.
Muteeb G; Alshoaibi A; Aatif M; Rehman MT; Qayyum MZ
Appl Biol Chem; 2020; 63(1):79. PubMed ID: 33251389
[TBL] [Abstract][Full Text] [Related]
25. Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL
Verma D; Mitra D; Paul M; Chaudhary P; Kamboj A; Thatoi H; Janmeda P; Jain D; Panneerselvam P; Shrivastav R; Pant K; Das Mohapatra PK
Curr Res Pharmacol Drug Discov; 2021; 2():100038. PubMed ID: 34870149
[TBL] [Abstract][Full Text] [Related]
26. Structural basis of SARS-CoV-2 3CL
Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
[TBL] [Abstract][Full Text] [Related]
27. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
[TBL] [Abstract][Full Text] [Related]
28. Screening of phytochemical compounds of
Krupanidhi S; Abraham Peele K; Venkateswarulu TC; Ayyagari VS; Nazneen Bobby M; John Babu D; Venkata Narayana A; Aishwarya G
J Biomol Struct Dyn; 2021 Sep; 39(15):5799-5803. PubMed ID: 32627715
[TBL] [Abstract][Full Text] [Related]
29. A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease.
Hernández González JE; Eberle RJ; Willbold D; Coronado MA
Front Mol Biosci; 2021; 8():816166. PubMed ID: 35187076
[TBL] [Abstract][Full Text] [Related]
30. The SARS-CoV-2 main protease (M
Hu Q; Xiong Y; Zhu GH; Zhang YN; Zhang YW; Huang P; Ge GB
MedComm (2020); 2022 Sep; 3(3):e151. PubMed ID: 35845352
[TBL] [Abstract][Full Text] [Related]
31. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Achutha AS; Pushpa VL; Suchitra S
J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
[TBL] [Abstract][Full Text] [Related]
32. New chalcone derivatives as effective against SARS-CoV-2 agent.
Duran N; Polat MF; Aktas DA; Alagoz MA; Ay E; Cimen F; Tek E; Anil B; Burmaoglu S; Algul O
Int J Clin Pract; 2021 Dec; 75(12):e14846. PubMed ID: 34519118
[TBL] [Abstract][Full Text] [Related]
33. Novel designed analogues of quercetin against SARS-CoV2:an in-silico pharmacokinetic evaluation, molecular modeling, MD simulations based study.
Shamim S; Akhtar M; Gul S
J Biomol Struct Dyn; 2023 Oct; ():1-19. PubMed ID: 37798928
[TBL] [Abstract][Full Text] [Related]
34. Identification of bioactive molecule from
Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
[TBL] [Abstract][Full Text] [Related]
35. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
36. In Silico Prediction of Novel Inhibitors of SARS-CoV-2 Main Protease through Structure-Based Virtual Screening and Molecular Dynamic Simulation.
Halim SA; Waqas M; Khan A; Al-Harrasi A
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577596
[TBL] [Abstract][Full Text] [Related]
37. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
Abdusalam AAA; Murugaiyah V
Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261
[TBL] [Abstract][Full Text] [Related]
38. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL
Vincent S; Arokiyaraj S; Saravanan M; Dhanraj M
Front Mol Biosci; 2020; 7():613401. PubMed ID: 33425994
[TBL] [Abstract][Full Text] [Related]
39. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
40. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
